


Research Article


Prevalence of *bla*_{IMP-1} among *P. aeruginosa* isolated from patients with burn infections

Ansam Adnan Ahmed Alghreri * 

Department of Biology, College of Sciences, University of Kerbala, Karbala, Iraq

Kawkab Abdalla Alsaadi 

Department of Biology, College of Sciences, University of Kerbala, Karbala, Iraq

Hussein O.M. Al-Dahmishi 

Department of Biology, College of Sciences, University of Babylon, Hilla, Iraq

*Corresponding author. Email: Laalghreri@gmail.com

Article Info

<https://doi.org/10.31018/jans.v14i3.3777>

Received: July 15, 2022

Revised: September 6, 2022

Accepted: September 11, 2022

How to Cite

Alghreri, A. A. A. *et al.* (2022). Prevalence of *bla*_{IMP-1} among *P. aeruginosa* isolated from patients with burn infections. *Journal of Applied and Natural Science*, 14(3), 1062 - 1066. <https://doi.org/10.31018/jans.v14i3.3777>

Abstract

Carbapenems are often used as antibiotics for treating infections by multidrug-resistant Gram-negative bacteria. *Pseudomonas aeruginosa* is considered a major cause of health care issues associated with higher mortality and morbidity rates worldwide. This study aimed to detect the prevalence of carbapenemase gene *bla*_{IMP-1} that is produced by carbapenem-resistant *P. aeruginosa* isolated from burn infection patients. A total of 137 burn swabs were collected from burn patients in different hospitals in Babylon province from December 2021 to April 2022. All of the swabs were streaked on selective media ceftrimide agar. Antibiotic susceptibility was performed for Imipenem and meropenem and polymerase chain reaction for species specific 16S rDNA gene and *bla*_{IMP-1} gene was done for all isolates. 50 isolates were confirmed by amplicon of species-specific 16S rDNA for *P. aeruginosa*. Results of antibiotic susceptibility for imipenem and meropenem revealed that 5/50 (10%) and 13/50(26%) of *P. aeruginosa* isolates were resistant to imipenem and meropenem, respectively. Co-susceptibility (co-resistance or co-sensitive) for both imipenem and meropenem results showed 5/50 (10%) display resistance for both imipenem and meropenem, 8/50 (16%) display resistance for only meropenem while 37/50(74%) sensitive for both and none was resistant to imipenem and sensitive for meropenem. Phenotypic detection of Metallo-β-lactamase gave inverse result while the Mean±SD of inhibition zone (mm) for imipenem disc (10µg) =29.34±7.11 and for imipenem+EDTA (10 µg+750 µg) =21.8±4.98. Investigation of *bla*_{IMP-1} gene revealed that 23/50 (46%) have *bla*_{IMP-1} while 18/50 (36%) were sensitive for imipenem and meropenem but have *bla*_{IMP-1}. The current study concludes the possibility of the presence of resistance gene among phenotypically sensitive isolates pushing great threat of antibiotic misuse and leaving the infection untreated.

Keywords: *bla*_{IMP-1}, burn patients, Carbapenems, Metallo-β-lactamase and *Pseudomonas aeruginosa*

INTRODUCTION

Pseudomonas aeruginosa is an opportunistic human pathogen capable of causing a great threat to health, especially in immunocompromised patients (Farhan *et al.*, 2019). It is the main cause of nosocomial infections and due to their ability to acquire resistance to a wide range of antibiotics making it a major global concern (Kumar and Illamani, 2021; Hashemi, *et al.*, 2021; Jafari-Sales *et al.*, 2020). It is responsible for a wide range of infections, including urinary tract, respiratory system, burn and wound infection and otitis media (Paudel *et al.*, 2021). *P. aeruginosa* is one of the most dangerous burn wound infections pathogens causing 75% of all deaths in patients and is considered a major medical

challenge because of its difficulty to treat (Farhan *et al.*, 2019).

Carbapenems antibiotics are effective against multidrug-resistant bacteria, but their widespread use yields in the emergence of resistant strains. Carbapenem hydrolyzing enzymes are assigned into four groups according to Ambler classification A, B, C and D (Paudel *et al.*, 2021; Vural *et al.*, 2020). The metallo-β-lactamase (MBLs) belong to group B and they require divalent cations (such as zinc ion) as cofactors for enzyme activity, which is inhibited by the action of a metal ion chelator such as EDTA and thiol-based compounds. This behavior is considered as dependent phenotype detection. The MBLs efficiently hydrolyze all beta lactams, except aztreonam and in vitro MBLs con-

sist of several variants of enzymes such as IMP, VIM, SPM, GIM and SIM (Marshall *et al.*, 2017). *P. aeruginosa* is often difficult to eradicate due to their resistant drug profile. Therefore, detection of MBL-producing *P. aeruginosa* is crucial for the optimal treatment of patients particularly in critically ill and hospitalized patients, and to control the spread of resistance (Safarirad *et al.*, 2021). *bla_{IMP-1}* was the most prevalent MBL among MDR-*P. aeruginosa* in Iraq (Al-Charrakh *et al.*, 2016; Alkhudhairy and Al-Shammari, 2020). This study aims to know the extent of the spread of *bla_{IMP-1}* in Babylon province, especially among burn patients.

MATERIALS AND METHODS

Samples collection

Babylon Health Directorate approved for the collection swaps from patients. Accordingly, a total of 137 burn swabs (102 female with age mean \pm SD= 36.17 \pm 21.23 and 48 male with age mean \pm SD= 34.56 \pm 19.09) were collected during the study period from hospitalized burn patients who showed signs suggestive of infection from December 2021 to April 2022. The samples were transported to transport swab and then submitted to bacteriological investigation.

Bacterial diagnosis

All swabs were cultured on cefrimide agar (Khalil *et al.*, 2021) plates at 37°C overnight for selective growth of *P. aeruginosa* isolates. All positive isolates will submit for polymerase chain reaction (PCR) to confirm them as *P. aeruginosa* using species specific primer pair for *P. aeruginosa* 16S rDNA gene. Forward primer (16S-PA-F): 5'GGGGGATCTTCGGACCTCA3', reverse primer (16S-PA-R): 5'TCCTTAGAGTGCCACCCG3', which annealed at 61°C to give 956 bp amplicon (Spilker *et al.*, 2004).

Antimicrobial susceptibility testing

All 50 confirmed *P. aeruginosa* isolates were tested for their antibiotic susceptibility patterns (for imipenem (10 μ g) and meropenem (10 μ g) according to CLSI-2021. The test was done on Mueller Hinton agar using the selected antibiotic discs. After 24 hours of incubation at 37°C, all samples were examined and inhibition zones

were measured and interpreted (Clinical and Laboratory Standards Institute, 2021).

Phenotypic detection of MBL production

Imipenem–EDTA combination disc testing was used for the detection of MBL-producing isolates. A solution of 0.5 M EDTA was prepared by dissolving 18.61 g of EDTA in 100 mL distilled water with pH 8, (Also used an artificial disc of imipenem/EDTA 10/750 was used). The tested isolates were cultured on Muller–Hinton agar plates. Two 10 μ g imipenem disks were placed on agar plates and 10 μ L EDTA solution added to one imipenem disc. Inhibition zones around discs with EDTA were measured after 18-24 hours' incubation at 37°C and compared with others without EDTA. An increase in zone diameter of at least 7 mm around the imipenem–EDTA disc was considered positive results (Chanu *et al.*, 2019).

Detection of *bla_{IMP-1}* MBL gene by PCR

DNA extraction was done by using FavorPrep™ Blood / Cultured Cell Genomic DNA Extraction Mini Kit (FABGK100) (Favorgen/Tiwan). The extracted DNA was subjected to PCR amplification reaction using specific primers for MBL genes (*bla_{IMP-1}*). The DNA amplification was done using GoTaq® Green Master Mix, 2X (M7122) (Promega/USA). The primers were purchased lyophilized; (Macrogen/Korea) and reconstituted by the addition of sterile nuclease free water and stored at –20°C. Forward primer (*blaIMP-F*): 5' TGAGCAAGTTATCTGTATTC3' and reverse primer (*blaIMP-R*): 5' TTAGTTGCTTGGTTTTGATG3' which annealed at 51°C to give 740 bp amplicon (Moosavian and Rahimzadeh, 2015).

RESULTS

The results of all 50 isolates grown on cefrimide agar submitted to confirmation by PCR for amplification of *P. aeruginosa* specific fragment of 16S rDNA revealed that all of them were *P. aeruginosa* (Fig. 1). Results of antibiotic susceptibility for imipenem and meropenem revealed that 5/50 (10%) and 13/50(26%) of *P. aeruginosa* isolates were resistant for imipenem and meropenem respectively (Fig. 2). Co-susceptibility (co-




Fig. 1. Agarose gel (1.5% in TBE) electrophoresis for *P. aeruginosa* specific amplicon of 16S rDNA (956bp)




Fig. 2. Antibiotic susceptibility of *P. aeruginosa* for imipenem and meropenem




Fig. 3. Co-susceptibility of *P. aeruginosa* for imipenem and meropenem. IMP-S=imipenem sensitive, IMP-R = imipenem resistant, MEM-S=meropenem sensitive, MEM-R=meropenem resistant

resistance or co-sensitive) for both imipenem and meropenem are highlighted in Fig. 3. It was revealed that 5/50 (10%) display resistance for both imipenem and meropenem, 8/50(16%) displayed resistance for only meropenem while 37/50(74%) was sensitive for both and none was resistant to imipenem and sensitive for meropenem. Phenotypic detection of Metallo-β-lactamase gave inverse result while the Mean±SD of inhibition zone (mm) for imipenem disc (10µg) =29.34±7.11 and for imipenem+EDTA (10 µg+750 µg)

Table 1. Phenotypic detection of Metallo-β-lactamase among *P. aeruginosa* isolates

Antibiotic	Inhibition zone (mm)
IMP	29.34±7.11
IMP+EDTA	21.8±4.98

=21.8±4.98 as mentioned in Table 1. Results of investigation of *bla*_{IMP-1} gene among 50 *P. aeruginosa* isolates revealed that 23/50 (46%) have *bla*_{IMP-1} (Fig. 4). Phenotypic resistance or sensitive isolate reflected the resistance gene content and so it was involved in routine work to predict resistance gene presence. The results of the relation of genotype to phenotype gave unexpected results when 18/50 (36%) were sensitive for imipenem and meropenem but had *bla*_{IMP-1} (Fig. 5) and this is the big issue when phenotypically sensitive isolates have a resistance gene.

DISCUSSION

The emergence of *P. aeruginosa* carbapenem-resistant represents a threat to the clinical approach because it decreased susceptibility to a range of antimicrobials and possesses ability to develop resistance to other classes (Morales et al., 2003). The current results reports that the percentages of *P. aeruginosa* in burns swabs are (36.49%), and this result is higher than in the Iraqi results of Ulabdeen in 2016 recorded (8.2%) (Ulabdeen, 2016), Al-Rubaye and colloquies in 2020 was (24.27%) (Al-Rubaye et al., 2020). This difference in rate may belong to the level of health care, the speed arrival of patient to the hospital, the patient had taken antibiotics in advance, or may be because of the long hospital hospitalisation. This percentage may increase within 72 hours due to an infection acquired from nosocomial infection due to contact with patients or through using of contaminated instruments that lead to spread these bacteria (Al-Rubaye et al., 2020). Other studies stated that resistance to imipenem 71% and meropenem was 63% (Al-Rubaye et al., 2020) and Azeez and Bakr 2019 showed resistant to imipenem and meropenem was 4% and 20%, respectively (Azeez




Fig. 4. Agarose gel (1.5% in TBE) electrophoresis for *P. aeruginosa* *bla*_{IMP-1} amplicon 40bp




Fig. 5. Presence of *bla*_{IMP-1} and Co-susceptibility among *P. aeruginosa* isolates

and Bakr, 2019). This variant may have occurred because the random use of antibiotics had an important role in the emergence of resistance to these antibiotics. However, in other countries such as Pakistan, the most common bacterial isolate from burn patients was *P. aeruginosa* with (24.91%) and showed resistance to different antibiotics including imipenem and meropenem (Chaudhary et al., 2019). In United States, most *P. aeruginosa* isolates had resistance to Carbapenems (Jenny and Kingsbury, 2018). In Philippines 31.1% has been reported resistance to imipenem, in Thailand 28.7%, Japan 28.5%, Singapore 23.3%, Korea 22%, and Romania 48%, and in Germany, Austria, Denmark, Finland, French, Luxemburg < 20% (Vaez et al., 2017). In Iran the prevalence of imipenem-resistant *P. aeruginosa* strains was 57.1% in Ardabil (Safarirad et al., 2021). In this study, the results revealed that 5/50 (10%) displayed resistance for both imipenem and meropenem, 8/50 (16%) displayed resistance for only meropenem while 37/50 (74%) sensitive for both and none was resistant to imipenem and sensitive for meropenem. Furthermore, the results of the investigation of *bla*_{IMP-1} gene among 50 *P. aeruginosa* isolates revealed that 23/50 (46%) - have *bla*_{IMP-1}, and these results of genotype detection was unidentical with most phenotypic method when the results are little invers of expected when found that the *bla*_{IMP-1} present in 36% sensitive isolates to imipenem and meropenem and this issue may be explained as gene silencing and no production of *bla*_{IMP-1} enzyme. The additional unexpected results were the decreasing the inhibition zone upon addition of EDTA to imipenem and it can be explained may be due to decreasing the uptake of IMP-EDTA combination of diminishing the uptake by porins. However, previous studies revealed variant percentages of *bla*_{IMP-1} prevalence, in Erbil was 57% (Azeez and Bakr, 2019), in Ardabil city was 35.5% (Safarirad et al., 2021), Iranian burn centers 76.8% (Jabalameli et al., 2018) and in Minia, Egypt was 42.8% (Farhan et al., 2019).

Conclusion

The results concluded implication of *bla*_{IMP-1} gene in resistance to carbapenem and the possibility of presence of a resistance gene among phenotypically sensitive isolates may push a great threat of misuse of antibiotics and leave the infection untreated.

Conflict of interest

The authors declare that they have no conflict of interest.

REFERENCES

1. Al Charrakh, A.H., Al Awadi, S. J. & Mohammed, A. S. (2016). Detection of metallo-β-lactamase producing *Pseudomonas aeruginosa* isolated from public and private hospitals in Baghdad, Iraq. *Acta Med Iran*, 54(2), 107–13.
2. Alkudhairy, M.K. & Al-Shammari, M. M. M. (2020). Prevalence of metallo-β-lactamase-producing *Pseudomonas aeruginosa* isolated from diabetic foot infections in Iraq. *New microbes and new infections*, 35, 100661. <https://doi.org/10.1016/j.nmni.2020.100661>.
3. Azeez, B.S. & Bakr, K. I. (2019). Phenotypic and molecular detection of metallo-β-lactamase producing *Pseudomonas aeruginosa* isolates from different clinical infections in Erbil. *Zanco Journal of Pure and Applied Sciences*, 31 (1), 46-56.
4. Chanu, T.R., Shah, P.K., Soni, S. & Ghosh, A.N. (2019). Phenotypic detection of extended spectrum, AmpC, Metallo beta-lactamases and their coexistence in clinical isolates of commonly isolated gram-negative bacteria in GKGH hospital, Bhuj. *Int J Med Microbiol Trop Dis*, 5(01), 52-56. <https://doi.org/10.18231/2581-4761.2019.0012>.
5. Chaudhary, N.A., Munawar, M.D., Khan, M.T., Rehan, K., Sadiq, A., Bhatti, H.W. & Rizvi, Z.A. (2019). Epidemiology, bacteriological profile, and antibiotic sensitivity pattern of burn wounds in the burn unit of a tertiary care hospital. *Cureus*, 11(6), e4794. <https://doi.org/10.7759/cureus.4794>
6. Clinical and Laboratory Standards Institute (2021). Performance standards for antimicrobial susceptibility testing. 31st. ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, USA.
7. Farhan, S.M., Ibrahim, R.A., Mahran, K.M., Hetta, H.F. & Abd El-Baky, R.M. (2019). Antimicrobial resistance pattern and molecular genetic distribution of metallo-β-lactamases producing *Pseudomonas aeruginosa* isolated from hospitals in Minia, Egypt. *Infection and Drug Resistance*, 12, 2125–2133. <https://doi.org/10.2147/IDR.S198373>
8. Hashemi, A.B., Nakhaei Moghaddam, M., Forghanifard, M.M. & Yousefi, E. (2021). Detection of blaOXA-10 and blaOXA-48 Genes in *Pseudomonas aeruginosa* Clinical Isolates by Multiplex PCR. *Journal of Medical Microbiology and Infectious Diseases*, 9(3), 142-147. DOI: 10.52547/JoMMID.9.3.142
9. Jabalameli, F., Taki, E., Emameini, M. & Beigverdi, R. (2018). Prevalence of metallo-β-lactamase-encoding genes among carbapenem-resistant *Pseudomonas aeruginosa* strains isolated from burn patients in Iran. *Revista da Sociedade Brasileira de Medicina Tropical*, 51(3), 270–

276. <https://doi.org/10.1590/0037-8682-0044-2018>.
10. Jafari-Sales, A. & Khaneshpour, H. (2020). Molecular Study of *BlaIMP* and *BlaVIM* Genes in *Pseudomonas Aeruginosa* Strains, Producer of Metallo Beta Lactamases Isolated from Clinical Samples in Hospitals and Medical Centers of Tabriz. *Paramedical Sciences and Military Health*, 14(4), 18-25.
 11. Jenny, M. & Kingsbury, J. (2018). Properties and prevention: A review of *Pseudomonas aeruginosa*. *J Biol Med Res*. Vol.2 No.3:18
 12. Khalil, M.A., El Maghraby, G.M., Sonbol, F.I., Allam, N.G., Ateya, P.S. & Ali, S.S. (2021). Enhanced efficacy of some antibiotics in presence of silver nanoparticles against multidrug resistant *Pseudomonas aeruginosa* recovered from burn wound infections. *Frontiers in microbiology*, 12, 648560. <https://doi.org/10.3389/fmicb.2021.648560>.
 13. Kumar, K.M. & Illamani, C.S. (2021). To Study The Antimicrobial Susceptibility Pattern Of *Pseudomonas Aeruginosa* And Detection Of Metallo Beta Lactamase Producing Strain With Special Reference To *BlaIMP-1* AND *BlaVIM*. *Annals Of The Romanian Society For Cell Biology*, 2998-3013.
 14. Marshall, S., Hujer, A.M., Rojas, L.J., Papp-Wallace, K.M., Humphries, R.M., Spellberg, B., Hujer, K.M., Marshall, E.K., Rudin, S.D., Perez, F. & Wilson, B.M. (2017). Can ceftazidime-avibactam and aztreonam overcome β -lactam resistance conferred by metallo- β -lactamases in Enterobacteriaceae?. *Antimicrobial agents and chemotherapy*, 61(4), e02243-16. <https://doi.org/10.1128/AAC.02243-16>.
 15. Moosavian, M. & Rahimzadeh, M. (2015). Molecular detection of metallo- β -lactamase genes, *blaIMP-1*, *blaVIM-2* and *blaSPM-1* in imipenem resistant *Pseudomonas aeruginosa* isolated from clinical specimens in teaching hospitals of Ahvaz. *Iranian journal of microbiology*, 7(1), 2-6.
 16. Morales, P., Fernández-García, E. & Núñez, M. (2003). Caseinolysis in cheese by Enterobacteriaceae strains of dairy origin. *Letters in Applied Microbiology*, 37(5), pp.410-414. <https://doi.org/10.1046/j.1472-765X.2003.01422>.
 17. Paudel, P., Shrestha, S., Poudel, S. & Tiwari, B.R. (2021). Multi-drug Resistant Bacteria Isolated from Pus and Phenotypic Detection of Metallo β -lactamase Activity of *Pseudomonas Aeruginosa*. *Nepal Journal of Health Sciences*, 1(1), 8–15. <https://doi.org/10.3126/njhs.v1i1.38604>.
 18. Safarirad, S., Arzanlou, M., Mohammadshahi, J., Vaez, H., Sahebkar, A. & Khademi, F. (2021). Prevalence and characteristics of metallo-beta-lactamase-positive and high-risk clone ST235 *Pseudomonas aeruginosa* at Ardabil hospitals. *Jundishapur Journal of Microbiology*, 14(3): e115819. doi: 10.5812/jjm.115819.
 19. AL-Rubaye Salman, M.R., Mohammed, T.K. & Abdullah, H.N. (2020). Isolation and Diagnosis of Multi Drug Resistance *Pseudomonas Aeruginosa* from Wound and Burnpatients in Baghdad City. *Indian Journal of Forensic Medicine & Toxicology*, 14(3), 2431–2437. <https://doi.org/10.37506/ijfnt.v14i3.10801>
 20. Spilker, T., Coenye, T., Vandamme, P. & LiPuma, J. J. (2004). PCR-based assay for differentiation of *Pseudomonas aeruginosa* from other *Pseudomonas* species recovered from cystic fibrosis patients. *Journal of clinical microbiology*, 42(5), 2074–2079. <https://doi.org/10.1128/JCM.42.5.2074-2079.2004>.
 21. Ulabdeen, S.M.Z. (2016). Bacteriological study for some aerobic bacteria contaminated the post-operative wounds. *Muthanna Medical Journal*, 3(1), 38-42.
 22. Vaez, H., Salehi-Abargouei, A. & Khademi, F. (2017). Systematic review and meta-analysis of imipenem-resistant *Pseudomonas aeruginosa* prevalence in Iran. *Germes*, 7(2), 86–97. <https://doi.org/10.18683/germs.2017.1113>.